Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?

被引:48
作者
Grimmsmann, Thomas [1 ]
Himmel, Wolfgang [2 ]
机构
[1] Med Review Board Statutory Hlth Insurance Funds M, Schwerin, Germany
[2] Univ Gottingen, Dept Gen Practice, Gottingen, Germany
关键词
Drug prescriptions; Drug utilisation review; Antihypertensive agents; Pharmacoepidemiology; Databases; PATTERNS; PERIOD;
D O I
10.1007/s00228-011-1014-7
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose Defined daily doses (DDD) are used for the measurement of drug utilisation. The aim of the study was to analyse whether differences between DDD and prescribed daily doses (PDD) exist for relevant drug classes such as antihypertensive drugs and, if so, whether they primarily depend on drug classes or patient-related factors. Methods Using the data of a large German statutory health insurance scheme, we analysed continuous prescriptions for the following antihypertensive drug classes: thiazide diuretics, beta-blockers, dihydropyridine calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs). We summed the doses of all dispensed drugs per person during a defined time frame. We calculated the PDD (= total dose divided by the number of days) and expressed them as the PDD: DDD ratio (= amount of DDD per day and person). Results During the study period, 149,704 patients continuously received an antihypertensive medication. The average PDD: DDD ratio ranged from 0.84 (beta-blockers) to 1.88 (ARBs) and 2.17 (ACEIs). The average prescribed dosage of each drug class remained unchanged, even if the patients had previously received another antihypertensive drug with another PDD: DDD ratio. For example, if patients were switched from a beta-blocker to an ACEI, the PDD:DDD ratio increased, on average, from 0.79 to 2.17. Vice versa, the ratio decreased for patients with a drug change from an ACEI to a beta-blocker from 2.06 to 0.75. Conclusions Even large differences between DDD and PDD seem to be a matter of drug classes and not primarily of patient characteristics.
引用
收藏
页码:847 / 854
页数:8
相关论文
共 22 条
[1]  
[Anonymous], HYP MAN AD PRIM CAR
[2]  
[Anonymous], 2009, GUID ATC CLASS DDD A
[3]   An approach for the estimation of drug prescribing using the defined daily dose methodology and drug dispensation data - Theoretical considerations and practical applications [J].
Cosentino, M ;
Leoni, O ;
Banfi, F ;
Lecchini, S ;
Frigo, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2000, 56 (6-7) :513-517
[4]   ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008 The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) [J].
Dickstein, Kenneth ;
Cohen-Solal, Alain ;
Filippatos, Gerasimos ;
McMurray, John J. V. ;
Ponikowski, Piotr ;
Poole-Wilson, Philip Alexander ;
Stromberg, Anna ;
van Veldhuisen, Dirk J. ;
Atar, Dan ;
Hoes, Amo W. ;
Keren, Andre ;
Mebazaa, Alexandre ;
Nieminen, Markku ;
Priori, Silvia Gluliana ;
Swedberg, Karl .
EUROPEAN JOURNAL OF HEART FAILURE, 2008, 10 (10) :933-989
[5]   Potential savings from an evidence-based consumer-oriented public education campaign on prescription drugs [J].
Donohue, Julie M. ;
Fischer, Michael A. ;
Huskamp, Haiden A. ;
Weissman, Joel S. .
HEALTH SERVICES RESEARCH, 2008, 43 (05) :1557-1575
[6]   Utilization of oral antihyperglycemic drugs over a 7-year period (1998-2004) in a Hungarian population and adherence to drug therapy [J].
Doró, P ;
Benko, R ;
Kosik, E ;
Matuz, M ;
Tóth, K ;
Soós, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 61 (12) :893-897
[7]   Using a pharmacoepidemiological approach to estimate diabetes type 2 prevalence in Portugal [J].
Duarte-Ramos, F ;
Cabrita, J .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2006, 15 (04) :269-274
[8]   Relation between Defined Daily Doses (DDD) and Prescribed Daily Doses: A 3-Month Analysis of Outpatient Data from a Statutory Health Insurance Company [J].
Grimmsmann, T. ;
Himmel, W. .
GESUNDHEITSWESEN, 2010, 72 (07) :412-418
[9]  
Harder S, 2009, INT J CLIN PHARM TH, V47, P104
[10]  
Hartz Ingeborg, 2007, BMC Clin Pharmacol, V7, P14, DOI 10.1186/1472-6904-7-14